help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buckway, C. K.
Right arrow Articles by Rosenfeld, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buckway, C. K.
Right arrow Articles by Rosenfeld, R. G.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 10 4754-4765
Copyright © 2002 by The Endocrine Society


Original Article

Insulin-Like Growth Factor Binding Protein-3 Generation as a Measure of GH Sensitivity

C. K. Buckway, K. A. Selva, K. L. Pratt, E. Tjoeng, J. Guevara-Aguirre and R. G. Rosenfeld

Department of Genetics (C.K.B.), Stanford University, Stanford, California 94305; Department of Pediatrics (K.A.S., K.L.P., E.T., R.G.R.), Oregon Health & Science University, Portland, Oregon 97239; and Institute of Endocrinology, Metabolism, and Reproduction (J.G.-A.), Quito, Ecuador

Address all correspondence and requests for reprints to: Karin A. Selva, M.D., Department of Pediatrics, Oregon Health & Science University, 707 SW Gaines Road, Child Development and Rehabilitation Center-Pediatrics (CDRC-P), Portland, Oregon 97201. E-mail: selvak{at}ohsu.edu.

Abstract

A total of 198 subjects were randomized to either high-dose (0.05 mg/kg·d) or low-dose (0.025 mg/kg·d) GH for 7 d; the alternate dose was then received after a 2-wk washout period. Groups included in the study were: normal, GH-insensitive (GHI; homozygous for the E180 splice mutation); heterozygous GHI (carriers of the E180 splice mutation); GH-deficient; and idiopathic short stature.

Serum IGF binding protein-3 (IGFBP-3) concentrations (collected on d 1, 5, and 8 of treatment weeks) were GH-dependent, with significant elevation by d 5 of treatment, regardless of dose, in all normal subjects. GHI subjects had low baseline IGFBP-3 and poor or no response to either low- or high-dose GH. Heterozygous subjects, however, did not differ from age-matched normals with regard to IGFBP-3 generation. All GH-deficient subjects had subnormal baseline concentrations of IGFBP-3; most, but not all, were able to generate levels into normal ranges by 8 d of therapy. Children with idiopathic short stature showed a better response in IGFBP-3 generation compared with that previously observed with IGF-I, reaching concentrations in normal range with either dose of GH, suggesting that any GHI in this group is relatively limited to IGF-I production.

For the diagnosis of GHI, the highest sensitivity (100%) and specificity (92%) was found on d 8 of the high-dose GH-IGFBP-3 generation test. Failure to raise both IGF-I and IGFBP-3 lowered sensitivity to 82–86% with low-dose GH, and 86–91% with high-dose GH.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
F. Peter, C. Savoy, H.-J. Ji, M. Juhasz, M. Bidlingmaier, and P. Saenger
Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency
Eur. J. Endocrinol., March 1, 2009; 160(3): 349 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o
The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, D. A. Price, P. Wilton, K. Albertsson-Wikland, and M. B. Ranke
Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2047 - 2054.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Lofqvist, E. Andersson, L. Gelander, S. Rosberg, L. Hulthen, W. F. Blum, and K. A. Wikland
Reference Values for Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) and the Ratio of Insulin-Like Growth Factor-I to IGFBP-3 throughout Childhood and Adolescence
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1420 - 1427.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal
Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society